A Perspective by Michael Feldenkrais, CEO of 4Cable TV International, Inc
In a groundbreaking revelation, the U.S. government has unveiled a trove of documents shedding light on the ongoing review of marijuana’s federal status. I, Michael Feldenkrais, CEO of 4Cable TV International, Inc, delve into the implications of this disclosure, marking the official confirmation of health officials recommending the placement of cannabis in Schedule III of the Controlled Substances Act (CSA).
The 252 pages of documents released by the Department of Health and Human Services (HHS) provide a detailed panorama. According to the HHS, cannabis is acknowledged to have “currently accepted medical use in treatment in the United States” and a “potential for abuse less than the drugs or other substances in Schedules I and II.” Noteworthy is the revelation that over 30,000 healthcare professionals across 43 U.S. jurisdictions are authorized to recommend medical marijuana for more than six million registered patients, spanning at least 15 medical conditions.
This Schedule III recommendation finds its roots in the assertion that marijuana possesses an accepted medical use. Attorney Matt Zorn played a pivotal role in bringing this information to light, having obtained the documents through a Freedom of Information Act (FOIA) request. The subsequent publication on his On Drugs blog confirmed the Schedule III recommendation.
The documents embark on an exploration of the government’s eight-factor analysis for scheduling drugs, emphasizing abuse potential, accepted medical use, safety, and risk of physical dependence. The comprehensive review took into account both current acceptance and scientific literature supporting medical uses.
Efficacy findings across various indications reveal a nuanced landscape, with emphasis on marijuana’s effectiveness in treating pain conditions, particularly neuropathic pain. Conducted by the Food and Drug Administration (FDA), the review did not find support for marijuana’s benefits in treating epilepsy or anxiety. Concerns were raised about the potential substantial risk of adverse events associated with treating PTSD with marijuana.
While acknowledging some benefits, the evidence falls short of an unequivocal endorsement of marijuana’s medical advantages. However, federal health officials assert that none of the systematic reviews identified safety concerns that would preclude marijuana’s use in indications with credible scientific support.
The safety comparison with other substances concludes that marijuana poses low risks to public health compared to drugs like heroin, cocaine, and benzodiazepines. The National Institute on Drug Abuse (NIDA) aligns with this assessment.
Reactions from key figures, such as Rep. Earl Blumenauer, founder of the Congressional Cannabis Caucus, highlight the significance of this development as a welcome step towards ending prohibition. As the cannabis industry navigates these evolving dynamics, the ultimate decision rests with the DEA, with the timing of any rescheduling announcement subject to speculation among advocates and observers.
This disclosure is pivotal, clarifying the HHS’s Schedule III classification recommendation for marijuana. While not signifying federal legalization, this decision, if accepted by the DEA, could eliminate research barriers and grant state-licensed cannabis businesses access to federal tax deductions currently restricted under IRS code 280E.
What this means to the future of 4Cable TV International, Inc., soon to be Category V Biotech, Inc., is profound. When rescheduled, the plant will be available for research, enabling our company to fulfill its goals of uncovering medicinal benefits. This opens new avenues for exploration, aligning with our commitment to advancing research and discovering the therapeutic potential of the plant. As the landscape evolves, 4Cable TV International, Inc. anticipates playing a significant role in contributing to the growing body of knowledge surrounding the medicinal applications of cannabis.
As the DEA’s final decision looms, the complex interplay between federal agencies and the potential implications of rescheduling come to the forefront. Advocates cite public sentiment, emphasizing the importance of supporting state-regulated markets for the safety of the American people.
Opposition from former DEA heads and White House drug czars contrasts with support from state attorneys general, framing rescheduling as a “public safety imperative.” The unfolding developments signify a critical juncture in the discourse around marijuana’s federal status, with diverse perspectives shaping the narrative.
In conclusion, the released documents offer a comprehensive insight into the government’s evaluation process, capturing the growing momentum for the rescheduling of marijuana and its far-reaching implications for the industry. The unfolding events continue to shape the trajectory of marijuana policy, reflecting the broader shift towards reevaluating its federal status and potential impacts on the industry.